Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00723-5
Robert A Watson, Darcy Ward, Pippa Corrie, Elisa Fontana, William Ince, Victoria Kunene, Siow-Ming Lee, Mark Linch, Nangi Lo, Christian Ottensmeier, Miranda Payne, David Pinato, Thomas Powles, Elizabeth Smyth, Stefan N Symeonides, Fiona Thistlethwaite, Ojas Rajkumar, Henry Li, Lennard Lee
{"title":"Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK","authors":"Robert A Watson, Darcy Ward, Pippa Corrie, Elisa Fontana, William Ince, Victoria Kunene, Siow-Ming Lee, Mark Linch, Nangi Lo, Christian Ottensmeier, Miranda Payne, David Pinato, Thomas Powles, Elizabeth Smyth, Stefan N Symeonides, Fiona Thistlethwaite, Ojas Rajkumar, Henry Li, Lennard Lee","doi":"10.1016/s1470-2045(25)00723-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00723-5","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145813996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00722-3
The Lancet Oncology
{"title":"Cancer consequences of the HIV funding crisis","authors":"The Lancet Oncology","doi":"10.1016/s1470-2045(25)00722-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00722-3","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145813999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00614-x
Prof Martin J van den Bent MD, Santoesha A Ghisai MSc, Prof Wolfgang Wick MD, Prof Marc Sanson MD, Alba Ariela Brandes MD, Prof Paul M Clement MD, Sara C Erridge MD, Prof Michael A Vogelbaum MD, Prof Anna K Nowak MD, Prof Jean-François Baurain MD, Prof Warren P Mason MD, Helen Wheeler MD, Prof Emeline Tabouret MD, Sanjeev Gill MD, Matthew Griffin MD, Walter Taal MD, Prof Roberta Rudà MD, Prof Michael Weller MD, Catherine McBain MD, Jaap C Reijneveld MD, Roelien H Enting MD, Sébastien Tran MD, Thierry Lesimple MD, Martin Kocher MD, Anja Gijtenbeek MD, Elizabeth Lim MD, Prof Ulrich Herrlinger MD, Prof Peter Hau MD, Frederic Dhermain MD, Kenneth Aldape MD, Prof Robert B Jenkins MD, Hendrikus Jan Dubbink PhD, Prof Johan M Kros MD, Prof Pieter Wesseling MD, Youri Hoogstrate PhD, Sarah Nuyens, Vassilis Golfinopoulos MD, C Mircea S Tesileanu MD, Thierry Gorlia PhD, Prof Pim French PhD, Brigitta G Baumert MD
The CATNON trial investigated the benefit of the addition of concurrent or adjuvant temozolomide to radiotherapy in individuals with anaplastic astrocytoma. We report the long-term follow-up of the study focusing on the individuals with isocitrate dehydrogenase (IDH) mutated (IDHmt) tumours.
{"title":"Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial","authors":"Prof Martin J van den Bent MD, Santoesha A Ghisai MSc, Prof Wolfgang Wick MD, Prof Marc Sanson MD, Alba Ariela Brandes MD, Prof Paul M Clement MD, Sara C Erridge MD, Prof Michael A Vogelbaum MD, Prof Anna K Nowak MD, Prof Jean-François Baurain MD, Prof Warren P Mason MD, Helen Wheeler MD, Prof Emeline Tabouret MD, Sanjeev Gill MD, Matthew Griffin MD, Walter Taal MD, Prof Roberta Rudà MD, Prof Michael Weller MD, Catherine McBain MD, Jaap C Reijneveld MD, Roelien H Enting MD, Sébastien Tran MD, Thierry Lesimple MD, Martin Kocher MD, Anja Gijtenbeek MD, Elizabeth Lim MD, Prof Ulrich Herrlinger MD, Prof Peter Hau MD, Frederic Dhermain MD, Kenneth Aldape MD, Prof Robert B Jenkins MD, Hendrikus Jan Dubbink PhD, Prof Johan M Kros MD, Prof Pieter Wesseling MD, Youri Hoogstrate PhD, Sarah Nuyens, Vassilis Golfinopoulos MD, C Mircea S Tesileanu MD, Thierry Gorlia PhD, Prof Pim French PhD, Brigitta G Baumert MD","doi":"10.1016/s1470-2045(25)00614-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00614-x","url":null,"abstract":"The CATNON trial investigated the benefit of the addition of concurrent or adjuvant temozolomide to radiotherapy in individuals with anaplastic astrocytoma. We report the long-term follow-up of the study focusing on the individuals with isocitrate dehydrogenase (<ce:italic>IDH</ce:italic>) mutated (<ce:italic>IDHmt</ce:italic>) tumours.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00601-1
John P Neoptolemos, Christoph Springfeld, Daniel Öhlund, Markus W Büchler, Christoph W Michalski
{"title":"The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer","authors":"John P Neoptolemos, Christoph Springfeld, Daniel Öhlund, Markus W Büchler, Christoph W Michalski","doi":"10.1016/s1470-2045(25)00601-1","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00601-1","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00531-5
Jasper K W Gerritsen MD PhD, Philipp Karschnia MD MSc, Prof Lorenzo Bello MD PhD, Prof Shawn Hervey-Jumper MD, Jacob S Young MD, Prof Kathleen Seidel MD, Djaina D Satoer PhD, Prof Oliver Schnell MD MHBA, Michael Parsons PhD, Brian V Nahed MD FACS, Grazia Menna MD, Nico Teske MD MSc, External Rater Panel, Keyoumars Ashkan, Marion Barberis, Chetan Bettegowda, Florien Boele, Richard W. Byrne, Daniel P. Cahill, Daniel Delev, Elke De Witte, Katharine Drummond, Johnny Duerinck, Gavin Dunn, Samuel Emerson, Yoshua Esquenazi, Christian F. Freyschlag, Marjolein Geurts, Rachel Grossman, Constantinos G. Hadjipanayis, Margret Jensdottir, Markus Klimek, Chanhung Lee, Amy Maguire, Alireza Mansouri, James M. Markert, Yoshitaka Narita, Alessandro Olivi, Johan Pallud, Karin Piil, Matthias Preusser, Alfredo Quinones-Hinojosa, Jane Skjøth-Rasmussen, Michael Sabel, Christian Senft, Susan Short, Ole S. Solheim, Walter Stummer, Andrea Szelényi, Einar O. Vik-Mo, Colin Watts, Michael Weller, Patrick Wen, Timothy R Smith MD PhD, Nader Sanai MD, Prof Sandro M Krieg MD MBA, Prof Philippe Schucht MD, Prof Marike L D Broekman MD PhD, Prof Steven De Vleeschouwer MD PhD, Prof Asgeir S Jakola MD PhD, Prof Martin J van den Bent MD PhD, Prof Susan M Chang MD, Michael A Vogelbaum MD PhD, Prof Arnaud J P E Vincent MD PhD, Prof Joerg-Christian Tonn MD, Prof Mitchel S Berger MD FACS
In adult patients with newly diagnosed or recurrent diffuse glioma, more extensive resection is associated with longer progression-free and overall survival. Intraoperative mapping techniques are used to safely increase the extent of resection by locating, monitoring, and preserving the function of potentially infiltrated brain during surgery. However, there is no consensus on the indications for intraoperative mapping, the optimal functional tests to be used intraoperatively, or intraoperative decision making. Furthermore, there are no consensus standardised neurological, language, and functional outcome assessments that should be applied pre-operatively and post-operatively. The Personalized Interventions and Outcomes in Neurosurgical Oncology Research (PIONEER) Consortium and the Response Assessment in Neuro-Oncology (RANO) resect group are collaborative, multidisciplinary efforts that aim to standardise and enhance research and clinical practices in surgical neuro-oncology. Here, both working groups review the evidence and provide recommendations in an effort to improve standardisation in intraoperative stimulation mapping, electrophysiological monitoring, and intraoperative decision making during glioma resections in adults. The Policy Review offers an intraoperative framework to reduce heterogeneity and improve the quality of clinical and scientific practice. In addition to standardising practices and improving individual patient outcomes, this Policy Review provides a foundation for better consistency between institutions and facilitates multicentre collaboration in surgical neuro-oncology. Ultimately, reducing heterogeneity might accelerate the development of personalised surgical care by enabling advanced computational modelling techniques.
{"title":"A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making","authors":"Jasper K W Gerritsen MD PhD, Philipp Karschnia MD MSc, Prof Lorenzo Bello MD PhD, Prof Shawn Hervey-Jumper MD, Jacob S Young MD, Prof Kathleen Seidel MD, Djaina D Satoer PhD, Prof Oliver Schnell MD MHBA, Michael Parsons PhD, Brian V Nahed MD FACS, Grazia Menna MD, Nico Teske MD MSc, External Rater Panel, Keyoumars Ashkan, Marion Barberis, Chetan Bettegowda, Florien Boele, Richard W. Byrne, Daniel P. Cahill, Daniel Delev, Elke De Witte, Katharine Drummond, Johnny Duerinck, Gavin Dunn, Samuel Emerson, Yoshua Esquenazi, Christian F. Freyschlag, Marjolein Geurts, Rachel Grossman, Constantinos G. Hadjipanayis, Margret Jensdottir, Markus Klimek, Chanhung Lee, Amy Maguire, Alireza Mansouri, James M. Markert, Yoshitaka Narita, Alessandro Olivi, Johan Pallud, Karin Piil, Matthias Preusser, Alfredo Quinones-Hinojosa, Jane Skjøth-Rasmussen, Michael Sabel, Christian Senft, Susan Short, Ole S. Solheim, Walter Stummer, Andrea Szelényi, Einar O. Vik-Mo, Colin Watts, Michael Weller, Patrick Wen, Timothy R Smith MD PhD, Nader Sanai MD, Prof Sandro M Krieg MD MBA, Prof Philippe Schucht MD, Prof Marike L D Broekman MD PhD, Prof Steven De Vleeschouwer MD PhD, Prof Asgeir S Jakola MD PhD, Prof Martin J van den Bent MD PhD, Prof Susan M Chang MD, Michael A Vogelbaum MD PhD, Prof Arnaud J P E Vincent MD PhD, Prof Joerg-Christian Tonn MD, Prof Mitchel S Berger MD FACS","doi":"10.1016/s1470-2045(25)00531-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00531-5","url":null,"abstract":"In adult patients with newly diagnosed or recurrent diffuse glioma, more extensive resection is associated with longer progression-free and overall survival. Intraoperative mapping techniques are used to safely increase the extent of resection by locating, monitoring, and preserving the function of potentially infiltrated brain during surgery. However, there is no consensus on the indications for intraoperative mapping, the optimal functional tests to be used intraoperatively, or intraoperative decision making. Furthermore, there are no consensus standardised neurological, language, and functional outcome assessments that should be applied pre-operatively and post-operatively. The Personalized Interventions and Outcomes in Neurosurgical Oncology Research (PIONEER) Consortium and the Response Assessment in Neuro-Oncology (RANO) resect group are collaborative, multidisciplinary efforts that aim to standardise and enhance research and clinical practices in surgical neuro-oncology. Here, both working groups review the evidence and provide recommendations in an effort to improve standardisation in intraoperative stimulation mapping, electrophysiological monitoring, and intraoperative decision making during glioma resections in adults. The Policy Review offers an intraoperative framework to reduce heterogeneity and improve the quality of clinical and scientific practice. In addition to standardising practices and improving individual patient outcomes, this Policy Review provides a foundation for better consistency between institutions and facilitates multicentre collaboration in surgical neuro-oncology. Ultimately, reducing heterogeneity might accelerate the development of personalised surgical care by enabling advanced computational modelling techniques.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"107 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00729-6
Quisette P Janssen, Jacob L van Dam, Marc G Besselink, Johanna W Wilmink, Marjolein Y V Homs, Geertjan van Tienhoven, Casper H J van Eijck, Bas Groot Koerkamp
{"title":"The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer – Authors' reply","authors":"Quisette P Janssen, Jacob L van Dam, Marc G Besselink, Johanna W Wilmink, Marjolein Y V Homs, Geertjan van Tienhoven, Casper H J van Eijck, Bas Groot Koerkamp","doi":"10.1016/s1470-2045(25)00729-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00729-6","url":null,"abstract":"","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145813993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00566-2
Prof Karim Fizazi MD, Prof Fred Saad MD, Teresa Alonso-Gordoa MD PhD, Bogdan Żurawski MD, Philippe Barthélémy MD PhD, Eric Voog MD, Hernán Javier Cutuli MD, Prof Tomas Buchler MD, Prof Dingwei Ye MD, Daniel Castellano MD, Mariusz Kwiatkowski MD, Prof Cagatay Arslan MD, Prof Martin Richardet MD, Constantine Alifrangis MD, Jeffrey C Goh MBBS, Karina Vianna MD, Prof Weiqing Han MD, Koji Hatano MD, Tilmann Todenhöfer MD, Prof Margitta Retz MD, Abhinav Srivastava MPhil, Chelsea Jin MD, Saurabh Gupta PhD, Gilda Trandafirescu MD, Arancha Campos MPharm, Chung-Wei Lee MD, Maximiliano van Kooten Losio MD, Sumit K Subudhi MD PhD
Androgen receptor pathway inhibitors (ARPIs) and docetaxel are established standards of care for chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). We aimed to assess the efficacy and safety of adding nivolumab to docetaxel versus docetaxel alone in ARPI-pretreated, chemotherapy-naive mCRPC.
{"title":"Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial","authors":"Prof Karim Fizazi MD, Prof Fred Saad MD, Teresa Alonso-Gordoa MD PhD, Bogdan Żurawski MD, Philippe Barthélémy MD PhD, Eric Voog MD, Hernán Javier Cutuli MD, Prof Tomas Buchler MD, Prof Dingwei Ye MD, Daniel Castellano MD, Mariusz Kwiatkowski MD, Prof Cagatay Arslan MD, Prof Martin Richardet MD, Constantine Alifrangis MD, Jeffrey C Goh MBBS, Karina Vianna MD, Prof Weiqing Han MD, Koji Hatano MD, Tilmann Todenhöfer MD, Prof Margitta Retz MD, Abhinav Srivastava MPhil, Chelsea Jin MD, Saurabh Gupta PhD, Gilda Trandafirescu MD, Arancha Campos MPharm, Chung-Wei Lee MD, Maximiliano van Kooten Losio MD, Sumit K Subudhi MD PhD","doi":"10.1016/s1470-2045(25)00566-2","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00566-2","url":null,"abstract":"Androgen receptor pathway inhibitors (ARPIs) and docetaxel are established standards of care for chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). We aimed to assess the efficacy and safety of adding nivolumab to docetaxel versus docetaxel alone in ARPI-pretreated, chemotherapy-naive mCRPC.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1016/s1470-2045(25)00612-6
Anne Sophie V M van den Heerik MD, Nanda Horeweg MD PhD, Marie A D Haverkort MD, Nienke Kuijsters MD PhD, Prof Stefan Kommoss MD, Friederike L A Koppe MD, Marlies E Nowee MD PhD, Henrike Westerveld MD PhD, Maria A A De Jong MD, Filip Frühauf MD PhD, Jeltsje S Cnossen MD PhD, Jan Willem M Mens MD, Jannet C Beukema MD PhD, Prof Cyrus Chargari MD PhD, Charles Gillham MD, Ina M Jurgenliemk-Schulz MD PhD, Prof Katrien Vandecasteele MD PhD, Moritz Hamann MD, Mandy Kiderlen MD PhD, Prof Annette Staebler MD PhD, Prof Hans W Nijman MD PhD, Bastiaan G Wortman MD PhD, Elefteria Asteinidou PhD, Stephanie M de Boer MD PhD, Wilbert B van den Hout PhD, Karen W Verhoeven-Adema PhD, Prof Remi A Nout MD PhD, Prof Hein Putter PhD, Prof Tjalling Bosse MD PhD, Prof Carien L Creutzberg MD PhD
PORTEC-4a investigated molecular risk profile-based individualised adjuvant treatment for women with high-intermediate risk endometrial cancer, aiming to reduce both overtreatment and undertreatment while optimising locoregional control.
{"title":"Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial","authors":"Anne Sophie V M van den Heerik MD, Nanda Horeweg MD PhD, Marie A D Haverkort MD, Nienke Kuijsters MD PhD, Prof Stefan Kommoss MD, Friederike L A Koppe MD, Marlies E Nowee MD PhD, Henrike Westerveld MD PhD, Maria A A De Jong MD, Filip Frühauf MD PhD, Jeltsje S Cnossen MD PhD, Jan Willem M Mens MD, Jannet C Beukema MD PhD, Prof Cyrus Chargari MD PhD, Charles Gillham MD, Ina M Jurgenliemk-Schulz MD PhD, Prof Katrien Vandecasteele MD PhD, Moritz Hamann MD, Mandy Kiderlen MD PhD, Prof Annette Staebler MD PhD, Prof Hans W Nijman MD PhD, Bastiaan G Wortman MD PhD, Elefteria Asteinidou PhD, Stephanie M de Boer MD PhD, Wilbert B van den Hout PhD, Karen W Verhoeven-Adema PhD, Prof Remi A Nout MD PhD, Prof Hein Putter PhD, Prof Tjalling Bosse MD PhD, Prof Carien L Creutzberg MD PhD","doi":"10.1016/s1470-2045(25)00612-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00612-6","url":null,"abstract":"PORTEC-4a investigated molecular risk profile-based individualised adjuvant treatment for women with high-intermediate risk endometrial cancer, aiming to reduce both overtreatment and undertreatment while optimising locoregional control.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145814005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}